National Total Current Assets vs Deferred Long Term Liab Analysis
NHI Stock | USD 77.87 0.73 0.95% |
National Health financial indicator trend analysis is infinitely more than just investigating National Health Investors recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether National Health Investors is a good investment. Please check the relationship between National Health Total Current Assets and its Deferred Long Term Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in National Health Investors. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Total Current Assets vs Deferred Long Term Liab
Total Current Assets vs Deferred Long Term Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of National Health Investors Total Current Assets account and Deferred Long Term Liab. At this time, the significance of the direction appears to have very strong relationship.
The correlation between National Health's Total Current Assets and Deferred Long Term Liab is 0.8. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of National Health Investors, assuming nothing else is changed. The correlation between historical values of National Health's Total Current Assets and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of National Health Investors are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Total Current Assets i.e., National Health's Total Current Assets and Deferred Long Term Liab go up and down completely randomly.
Correlation Coefficient | 0.8 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Most indicators from National Health's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into National Health Investors current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in National Health Investors. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. As of now, National Health's Selling General Administrative is increasing as compared to previous years. The National Health's current Enterprise Value is estimated to increase to about 3.7 B, while Discontinued Operations is projected to decrease to under 16.4 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 287.1M | 268.4M | 308.3M | 169.0M | Total Revenue | 298.7M | 278.2M | 319.8M | 170.8M |
National Health fundamental ratios Correlations
Click cells to compare fundamentals
National Health Account Relationship Matchups
High Positive Relationship
High Negative Relationship
National Health fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.0B | 3.1B | 2.8B | 2.5B | 2.5B | 1.3B | |
Short Long Term Debt Total | 1.5B | 2.0B | 1.3B | 1.6B | 1.1B | 618.4M | |
Total Stockholder Equity | 1.5B | 1.5B | 1.5B | 1.3B | 1.3B | 729.6M | |
Net Debt | 1.4B | 1.5B | 1.2B | 1.1B | 1.1B | 1.2B | |
Retained Earnings | (5.3M) | (22.0M) | (84.6M) | (329.6M) | 2.5B | 2.6B | |
Non Currrent Assets Other | (308K) | 6.8M | 7.5M | 965K | 8.4M | 8.0M | |
Other Assets | 304.3M | 2.8B | 2.5B | 45.5M | 2.1B | 2.2B | |
Common Stock Shares Outstanding | 43.7M | 44.7M | 45.7M | 44.8M | 43.4M | 32.0M | |
Liabilities And Stockholders Equity | 3.0B | 3.1B | 2.8B | 2.5B | 2.5B | 1.3B | |
Non Current Liabilities Total | 1.5B | 1.5B | 1.3B | 1.1B | 1.2B | 1.3B | |
Other Stockholder Equity | 1.5B | 1.6B | 1.6B | 1.6B | (863.1M) | (819.9M) | |
Total Liab | 1.5B | 1.6B | 1.3B | 1.2B | 1.2B | 610.1M | |
Non Current Assets Total | 2.6B | 2.7B | 2.3B | 2.1B | 2.1B | 1.2B | |
Net Receivables | 429.4M | 390.7M | 399.4M | 315.0M | 330.0M | 238.6M | |
Total Current Assets | 463.5M | 437.1M | 505.2M | 379.8M | 352.3M | 256.7M | |
Other Current Liab | 45.6M | (408.6M) | (34.1M) | (376.4M) | (109.7M) | (104.2M) | |
Total Current Liabilities | 92.9M | 87.6M | 70.2M | 70.0M | 6.0M | 5.7M | |
Accounts Payable | 26.3M | 25.2M | 23.2M | 25.9M | 34.3M | 36.0M | |
Cash | 5.2M | 43.3M | 37.4M | 19.3M | 22.3M | 34.0M | |
Cash And Short Term Investments | 5.2M | 43.3M | 37.4M | 19.3M | 22.3M | 21.2M | |
Common Stock Total Equity | 446K | 452K | 459K | 434K | 499.1K | 351.3K | |
Accumulated Other Comprehensive Income | (3.4M) | (7.1M) | (84.6M) | (329.6M) | (350.2M) | (332.7M) | |
Common Stock | 446K | 452K | 459K | 434K | 499.1K | 355.8K | |
Short Term Debt | 1.2M | 458.4M | 75.4M | 415.4M | 75.4M | 63.4M | |
Other Liab | 30.4M | 23.3M | 14.6M | 5.1M | 4.5M | 4.3M | |
Long Term Debt | 1.4B | 1.5B | 1.2B | 1.1B | 1.1B | 663.6M | |
Current Deferred Revenue | 19.8M | 12.6M | 5.7M | 5.1M | 6.0M | 4.6M | |
Other Current Assets | (431.4M) | (431.5M) | (433.6M) | 45.5M | 13.5M | 14.2M | |
Net Tangible Assets | 1.5B | 1.5B | 1.5B | 1.3B | 1.5B | 1.2B | |
Capital Surpluse | 1.5B | 1.5B | 1.6B | 1.6B | 1.8B | 1.2B | |
Deferred Long Term Liab | 10.1M | 12.6M | 5.7M | 5.1M | 5.8M | 4.6M | |
Long Term Investments | 141.5M | 246.1M | 292.4M | 300.0M | 344.9M | 187.0M |
Currently Active Assets on Macroaxis
When determining whether National Health Investors offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of National Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of National Health Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on National Health Investors Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in National Health Investors. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Diversified REITs space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of National Health. If investors know National will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about National Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.14) | Dividend Share 3.6 | Earnings Share 2.91 | Revenue Per Share 7.598 | Quarterly Revenue Growth (0.12) |
The market value of National Health Investors is measured differently than its book value, which is the value of National that is recorded on the company's balance sheet. Investors also form their own opinion of National Health's value that differs from its market value or its book value, called intrinsic value, which is National Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because National Health's market value can be influenced by many factors that don't directly affect National Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between National Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if National Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, National Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.